Displaying drugs 9276 - 9300 of 11698 in total
BIA
Experimental
Matched Iupac: … 1-(3,4-dihydroxy-5-nitrophenyl)-3-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}propan-1-one …
Niguldipine
Niguldipine is a calcium channel blocker drug (CCB) with a1-adrenergic antagonist properties.
Experimental
Matched Iupac: … 3-[3-(4,4-diphenylpiperidin-1-yl)propyl] 5-methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine …
Matched Categories: … Heterocyclic Compounds, 1-Ring ... Adrenergic alpha-1 Receptor Antagonists …
Matched Categories: … Heterocyclic Compounds, 1-Ring ... Adrenergic alpha-1 Receptor Antagonists …
ICI-164384
Experimental
AVR118
AVR118 represents a new type of biopolymer chemistry that also possesses novel immunomodulator activity. This non-toxic peptide-nucleic acid, which to date has shown no indication of human toxicity, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papilloma virus and to dampen aberrant...
Investigational
REV131
rEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.
Investigational
V1003
V1003 is an intranasal formulation of buprenorphine, an opiate analgesic, for the management of post-operative pain in hospital and home settings. Buprenorphine is a well-known analgesic and the intranasal formulation has the potential to provide a convenient alternative to other treatments, allowing patients to manage their post-operative pain both prior...
Investigational
OBE101
OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine. Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management...
Investigational
R1204
R1204 is G-protein-coupled receptor modulator. It is developed for the treatment of depression.
Investigational
CAD106
CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients.
Investigational
PDPSC18
PDPSC18 is therapeutic DNA vaccine designed to fight chronic infections with the Hepatitis B virus, entering phase I clinical trials.
Investigational
CYC116
CYC116 is a novel anticancer compound with a unique target profile involving both cell cycle and angiogenesis inhibition mechanisms. In preclinical studies, CYC116 has demonstrated antitumor activity in both solid tumors and hematological cancers.
Cyclacel's small molecule investigational drug, CYC116, is the third orally-available Cyclacel drug to enter development, which...
Investigational
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Actelion-1
Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.
Investigational
Matched Name: … Actelion-1 …
Matched Description: … Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Description: … Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
BNC105
Investigational
Matched Iupac: … {[6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)-1-benzofuran-7-yl]oxy}phosphonic acid …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
ALGRX 1207
ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel. ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.
Investigational
BMS-188797
BMS-188797 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Matched Iupac: … (1S,2S,3R,4S,7R,9S,10S,12R,15S)-12-(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido ... methoxycarbonyl)oxy]-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2- …
Gold Au-198
Experimental
IMM101
IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID: 21930686; PMID: 30107850; PMID: 27599039]. Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help...
Investigational
MEM136
Investigational
AIC100
Investigational
ATX-F8-117
ATX-F8-117 is an investigational peptide derived from Factor VIII. Developed by Apitope, it is being investigated for the treatment of hemophilia A.
Investigational
4A10
Investigational
FLT190
FLT190 is a recombinant adeno-associated viral vector serotype S3 containing DNA encoding for human alpha-galactosidase A.
Investigational
CTX120
CTX120 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting B-cell maturation antigen.
Investigational
CTX110
CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.
Investigational
Displaying drugs 9276 - 9300 of 11698 in total